Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection.
Kolkman JJ, Tan TG, Oudkerk Pool M, Van Kleef WA, Geraedts AA, Timmerman RJ, Crobach LF, Nicolai JJ, Wolff AA, Van Der Laan J. Kolkman JJ, et al. Among authors: wolff aa. Aliment Pharmacol Ther. 1997 Dec;11(6):1123-9. doi: 10.1046/j.1365-2036.1997.00254.x. Aliment Pharmacol Ther. 1997. PMID: 9663840 Free article. Clinical Trial.
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, Corcia P, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA. Shefner JM, et al. Among authors: wolff aa. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):523-534. doi: 10.1080/21678421.2023.2216223. Epub 2023 May 30. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37254449 Clinical Trial.
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Butzner M, Chiò A, Andrews JA, Genge A, Hughes DA, Jackson CE, Lechtzin N, Miller TM, Shefner JM. Gebrehiwet P, et al. Among authors: wolff aa. J Med Econ. 2023 Jan-Dec;26(1):488-493. doi: 10.1080/13696998.2023.2192588. J Med Econ. 2023. PMID: 36930042 Free article. Clinical Trial.
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Chiò A, Andrews JA, Genge A, Jackson CE, Lechtzin N, Miller TM, Shefner JM. Gebrehiwet P, et al. Among authors: wolff aa. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):304-310. doi: 10.1080/21678421.2022.2154678. Epub 2022 Dec 12. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36503310 Clinical Trial.
Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Genge A, Johnson NE, Tesi-Rocha C, Connolly AM, Darras BT, Felice K, Finkel RS, Shieh PB, Mah JK, Statland J, Campbell C, Habib AA, Kuntz NL, Oskoui M, Day JW. Rudnicki SA, et al. Among authors: wolff aa. Neurotherapeutics. 2021 Jul;18(3):2130. doi: 10.1007/s13311-021-01120-8. Neurotherapeutics. 2021. PMID: 34731415 Free PMC article. No abstract available.
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial.
Rudnicki SA, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Shefner JM; FORTITUDE-ALS STUDY GROUP. Rudnicki SA, et al. Among authors: wolff aa. Amyotroph Lateral Scler Frontotemporal Degener. 2022 May;23(3-4):263-270. doi: 10.1080/21678421.2021.1946083. Epub 2021 Jul 5. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 34218726 Clinical Trial.
Noninvasive ventilation use by patients enrolled in VITALITY-ALS.
Rudnicki SA, Andrews JA, Bian A, Cockroft BM, Cudkowicz ME, Hardiman O, Malik FI, Meng L, Wolff AA, Shefner JM; VITALITY-ALS STUDY GROUP. Rudnicki SA, et al. Among authors: wolff aa. Amyotroph Lateral Scler Frontotemporal Degener. 2021 Nov;22(7-8):486-494. doi: 10.1080/21678421.2021.1904993. Epub 2021 Apr 1. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 33792451 Clinical Trial.
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Genge A, Johnson NE, Tesi-Rocha C, Connolly AM, Darras BT, Felice K, Finkel RS, Shieh PB, Mah JK, Statland J, Campbell C, Habib AA, Kuntz NL, Oskoui M, Day JW. Rudnicki SA, et al. Among authors: wolff aa. Neurotherapeutics. 2021 Apr;18(2):1127-1136. doi: 10.1007/s13311-020-01004-3. Epub 2021 Feb 23. Neurotherapeutics. 2021. PMID: 33624184 Free PMC article. Clinical Trial.
47 results